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Introduction: Outcome predictors in use today are prognostic only for hormone receptor-positive (HRpos) breast
cancer. Although microarray-derived multigene predictors of hormone receptor-negative (HRneg) and/or triple
negative (Tneg) breast cancer recurrence risk are emerging, to date none have been transferred to clinically suitable
assay platforms (for example, RT-PCR) or validated against formalin-fixed paraffin-embedded (FFPE) HRneg/Tneg
samples.
Methods: Multiplexed RT-PCR was used to assay two microarray-derived HRneg/Tneg prognostic signatures IR-7 and
Buck-4) in a pooled FFPE collection of 139 chemotherapy-naïve HRneg breast cancers. The prognostic value of the RT-
PCR measured gene signatures were evaluated as continuous and
dichotomous variables, and in conditional risk models incorporating clinical parameters. An optimized five-gene index
was derived by evaluating gene combinations from both signatures.
Results: RT-PCR measured IR-7 and Buck-4 signatures proved prognostic as continuous variables; and conditional risk
modeling chose nodal status, the IR-7 signature, and tumor grade as significant predictors of distant recurrence (DR).
From the Buck-4 and IR-7 signatures, an optimized five-gene (TNFRSF17, CLIC5, HLA-F, CXCL13, XCL2) predictor was gen-
erated, referred to as the Integrated Cytokine Score (ICS) based on its functional pathway linkage through interferon-γ
and IL-10. Across all FFPE cases, the ICS was prognostic as either a continuous or dichotomous variable, and conditional
risk modeling selected nodal status and ICS as DR predictors. Further dichotomization of node-negative/ICS-low
FFPE cases identified a subset of low-grade HRneg tumors with <10% 5-year DR risk. The prognostic value of ICS
was reaffirmed in two previously studied microarray assayed cohorts containing 274 node-negative and chemotherapy
naive HRneg breast cancers, including 95 Tneg cases where it proved prognostically independent of Tneg molecular
subtyping. In additional HRneg/Tneg microarray assayed cohorts, the five-gene ICS also proved prognostic irrespective
of primary tumor nodal status and adjuvant chemotherapy intervention.
Conclusion: We advanced the measurement of two previously reported microarray-derived HRneg/Tneg breast cancer
prognostic signatures for use in FFPE samples, and derived an optimized five-gene Integrated Cytokine Score (ICS) with
multi-platform capability of predicting metastatic outcome from primary HRneg/Tneg tumors independent of nodal
status, adjuvant chemotherapy use, and Tneg molecular subtype.* Correspondence: cbenz@buckinstitute.org
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About 20 to 30% of all newly diagnosed breast malignan-
cies are hormone receptor-negative (HRneg), including
the approximately 15% referred to as triple-negative
(Tneg), because they lack tumor cell overexpression of
estrogen and progesterone receptors (ER, PR) as well as
the human epidermal growth factor receptor-2 (HER2)
[1,2]. While known to be clinically and molecularly het-
erogeneous [3,4], HRneg and Tneg breast cancers are
considered significantly more aggressive than hormone
receptor-positive (HRpos) breast cancers, given that
their recurrence risk is manifested early, usually within
five years of primary tumor diagnosis regardless of adju-
vant or neoadjuvant chemotherapy intervention [2-4].
Despite maximal local and systemic therapy, the five-
year risk of metastatic recurrence and death for women
with node-positive HRneg disease is more than three-
fold higher than for node-positive HRpos breast cancer
patients [5-7]. However, this recurrence risk does not
persist beyond five years and, despite the early recur-
rence risk, nearly two-thirds of newly diagnosed early-
stage (T1,2 N0,1) HRneg and Tneg cases conservatively
managed without systemic therapy remain disease-free
five years or more after diagnosis. This suggests that
some newly diagnosed early-stage HRneg cases have a
good prognosis and may not require systemic therapy
for curative intent if accurate biomarkers predictive of
metastatic relapse were clinically available [8].
A meta-analyses of various multigene breast cancer
signatures, including the 70-gene NKI (MammaPrint)
profile [9], the MS-14 [10], EMC-76 [11], CSR/wound-
response [12], Oncotype Recurrence Score [13], p53 [14]
and the genomic grade index [15], concluded that their
prognostic values are comparable when evaluated in
HRpos breast cancers, presumably due to the fact that
the proliferation modules within these diverse gene sig-
natures are a common driving force behind their overall
prognostic performance [16,17]. By contrast, HRneg breast
cancers are more proliferative and are usually classified as
high risk or are not the appropriate target population for
these prognostic signatures. However, newer prognostic
signatures, not dependent on proliferation gene modules
but rather functionally linked to immune/inflammatory
and chemokine pathways, have been proposed as meta-
static risk predictors for HRneg/Tneg breast cancers.
These include the STAT1 cluster [18], the IFN cluster
[19], the IR-7 [20,21], the Buck-14 [22], the TN-45 [23]
and a B-cell/IL-8 metagene ratio [24].
Curiously, unlike HRpos prognostic signatures in which
elevated expression of the majority of gene components is
associated with increased tumor proliferation and poorer
prognosis, a consistent finding among HRneg predictors
described to date is that increased expression of their
specific gene components - particularly those linked toimmune/inflammatory and chemokine networks - is as-
sociated with better prognosis, although the directional
values of their composite indices are adjusted so that a
higher index value correlates with poorer outcome
[22,23]. Despite being composed of different gene sets,
some of these HRneg signatures appear to be strongly
intercorrelated (for example, Pearson correlation (Rp)
values of 0.72 to 0.96 between IR-7, STAT1 and IFN in-
dices, depending on dataset) [22], while others like the
Buck-14 index show a positive but much weaker correl-
ation with the other HRneg indices. Nonetheless, the
Buck-14 signature contains individual genes like
CXCL13 (ligand for the chemokine receptor CXCR5)
that correlate significantly with each of the IR-7 genes,
suggesting surrogate representation of the IR-7 index
within the Buck-14 index, in addition to prognostic fea-
tures not previously linked to immune/inflammatory or
cytokine responses [22]. Of note, all of the HRneg prognos-
tic indices described to date were developed using expres-
sion microarray data from fresh/frozen tumor-extracted
RNA. Unfortunately, none have yet been transferred to
other more commonly used gene measurement platforms,
such as multiplexed reverse transcription-polymerase
chain reaction (RT-PCR) assays, nor have any been pro-
spectively validated on clinical samples of formalin-fixed
and paraffin-embedded (FFPE) HRneg breast cancers.
The present study reports the transfer of two multigene
signatures (Buck-14, IR-7) capable of predicting metastatic
recurrence risk for HRneg/Tneg breast cancers from
microarray-based gene expression profiles on fresh/frozen
tumor samples to an RT-PCR assay platform suitable
for use with FFPE tumor samples. Following transfer of
the previously reported IR-7 and Buck-14 signatures to
a multiplexed RT-PCR assay platform, we compared these
signatures and then combined genes from both these sig-
natures to derive an optimized five-gene Integrated Cyto-
kine Score (ICS), whose prognostic performance was
verified across assay platforms and using various HRneg/
Tneg datasets.
Materials and methods
The overall schema for the analysis plan presented in
this manuscript is shown in Figure 1. The methods for
each component of the analysis are described below.
Prioritization of buck-14 signature genes
In anticipation of limited FFPE tumor section RNA avai-
lability, we prioritized the 14 microarray-derived genes
comprising the Buck-14 signature into a minimal set of
high priority genes showing the most robust prognostic
value across the two pooled expression microarray data-
sets described in our previous report (training set (n =
199) and validation set (n = 75), respectively) [22]. The
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Figure 1 Overall schema of analysis plan. Blue boxes show the assay platform advancement and the developmental progression of ICS as a
prognostic biomarker (discovery, validation and optimization). Black boxes show the signatures assessed at each stage of development.
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(DMFS) (P <0.15) in a multivariate Cox proportional
hazard model containing all 14 signature genes within
the training set; (2) a trend for association with DMFS
(P <0.15) within the validation set in a univariate or
multivariate Cox regression analysis; and (3) statistical
significance (P <0.05) in one of the above described Cox
regression analyses. Only genes passing all three criteria
were assigned high priority and used for prognostic
value assessment in the new FFPE collection of 139
chemotherapy-naïve HRneg breast cancer specimens.
FFPE collection of HRneg breast cancers and RT-PCR
measurement of signature genes
FFPE sections from chemotherapy naïve HRneg breast
cancers annotated with distant recurrence information
(minimum five-year clinical follow-up) were obtained from
the Mayo Clinic, the Guy’s Hospital and the California
Pacific Medical Center (CPMC). Patients gave theirinformed consent to their respective institutions for the
future research use of their samples, and the research
studies described here were approved by those institu-
tional review boards, including Guy’s Research Ethics
Committee, the Mayo Clinic Institutional Review Board
and the UCSF Committee on Human Research. HR (ER,
PR) status was as determined by the source sites, with
the exception of the Guy’s Hospital samples where HR
status was re-evaluated by IHC with available tissue
[25]. Only the 139 samples annotated for distant (metastatic)
recurrence and re-assessed as HRneg (ER-negative and
PR-negative) were considered evaluable; these included 58
from Mayo Clinic, 45 from Breast Tissue and Data Bank,
Guy’s Hospital, London and 36 from CPMC. A summary
of the clinical characteristics of the pooled FFPE cohort by
source site is shown in Table 1.
RNA extraction and RT-PCR gene expression assays
followed our previously described methods [10]. Total
RNA was extracted from 10 micron FFPE sections using
Table 1 Clinical summary of the pooled cohort of FFPE
HRneg samples analyzed by RT-PCR




Year diagnosed 1997 to 2001 1975 to 1986 1975 to 1982
HER2 status
HER2- 14 29 32
HER2+ 7 6 12
Borderline (2+) 2 0 0
Not determined 35 1 1
Nodal status
LN- 33 36 29
LN+ 24 0 16
Not determined 1 0 0
Grade
I 0 1 1
II 18 10 12
III 40 24 32
Not determined 0 1 0
Tumor size (cm)
Median (range) 2.1 (0.7 to 10) 1.5 (0.7 to 2.5) 3 (0 to 6)
Follow-up time
Median 3.7 8.98 13.65
Distant recurrence
Yes 16 6 13
No 42 30 32
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Research, Irvine, CA, USA). The FFPE sections were
digested with proteinase K for 18 to 24 hours at 55°C,
spun down and the supernatant treated with a mixture
of 100% ethanol and a GuSCN-based extraction buffer.
The extracted material was purified on Zymo-Spin II
columns, eluted with TE buffer and the RNA reverse
transcribed into cDNA using random hexamers and the
High Capacity cDNA kit (Life Technologies Grand
Island, NY, USA). Expression levels of the genes of
interest plus two reference genes (NUP214 and PPIG)
ere quantified with six multiplex RT-PCR TaqMan as-
says. The composition of genes in each of the multiplexes
and the primer sequences are shown in Additional file 1:
Table S1. The probe for each gene within a multiplex is la-
beled with a unique fluorophore with the exception of the
two reference genes which were both labeled with NED in
the same mix. Amplifications were performed with Ampli-
Taq Gold in a buffer containing 15 mM Tris–HCl, 50 mM
KCl, pH 8.0, 2.5 mM MgCl2, 200 uM dAGC, 400 uM
dUTP and uracil-N-glycolysis. The expression level of
each gene was determined using the ΔΔCT methodwhereby the Ct of each gene was first normalized to the
reference genes and then to a universal human reference
RNA (Stratagene Santa Clara, CA, USA) that was ampli-
fied with the same genes. Missing ΔΔCT values excluded
from analysis were due to a combination of low RNA in-
put and poor primer efficiency causing lack of expected
gene amplification within 40 thermocycles.
To create the final RT-PCR measured gene expression
dataset, ΔΔCT values for each gene were first median-
centered across samples within individual source sites
and then combined. The CT and ΔΔCT values, along
with the final RT-PCR measured gene expression data-
sets used in our analysis are provided in Additional file
2: Table S2. We performed unsupervised clustering of
samples and signature genes using the heatmap.2 func-
tion in the R package gplots [26]. To assess potential
source biases, we compared the composition of branches
of the sample dendrogram using the Fisher Exact test.
Prognostic performance of the IR-7 and Buck-4 signatures
Distant metastatic recurrence (DR) was our primary
endpoint of interest for evaluating prognostic perform-
ance in our pooled FFPE cohort of RT-PCR measured
gene expression. We first assessed the association be-
tween DR and expression levels of individual genes by
Cox proportional hazard model. The IR-7 and Buck-4
signature indices were then computed as follows:
IR−7 index ¼ SPP1−ðC1QAþ HLAF
þIGCL2þ LY9þ TNFRSF17þ XCL2Þ
7
Buck−4 index ¼ RGS4− CLIC5þ CXCL13þ FLJ46061ð Þ
4
For patients with missing ΔΔCT values in any of the
IR-7 signature genes (n = 20), the IR-7 index was not
computed. Of note, the above formulae were designed to
take into account the expected association between sig-
nature gene expression and recurrence risk [20,22], such
that higher indices would associate with increased DR
risk. Index values were then Z-transformed (that is,
scaled to a sample population mean of 0 and standard
deviation of 1). We evaluated the prognostic perform-
ance of these indices as continuous variables by Cox re-
gression analysis. The Harrell’s C statistic was used to
assess the resulting Cox model fit as a predictor of DR
risk. In addition, we dichotomized the pooled RT-PCR/
FFPE dataset into high vs. low index (IR-7, Buck-4) groups
by their median values. Significance in Kaplan-Meier
curve separation between index groups was assessed
using the log rank test.
Recursive partitioning was performed using the R pack-
age rpart to identify an optimal conditional model for DR
risk prediction [27]. We implemented a minimum
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cern for model stability. Input variables included tumor
grade, nodal status, and the IR-7 and Buck-4 signature
scores. The complexity parameter giving the smallest 10-
fold cross validation error was selected to generate the
final rpart tree.
Combining IR-7 and Buck-4 genes into an optimized mul-
tigene signature
Anticipating limited FFPE tumor section RNA availabil-
ity in future validation sets, we sought to identify an op-
timized predictor from both the IR-7 and Buck-4
signatures using a minimal gene set. We employed for-
ward stepwise selection to combine components of the
IR-7 and Buck-4 signatures into an optimal multigene
predictor of DR risk. Briefly, genes were added one at a
time to the signature, beginning with the one most sig-
nificantly associated with DR. At each step, signature in-
dices were computed for all possible additions and
evaluated by Cox regression analysis to select the opti-
mal order of addition and gene subsets yielding the best
overall model fit (that is, minimum likelihood ratio test
P-value). We then used the Ingenuity Pathway Analysis
software to identify potential functional network links
between the selected genes through a shortest path.
Based on these findings, an optimized five-gene Inte-
grated Cytokine Score (ICS) was defined. The ICS was
computed as follows and Z-transformed:
ICS ¼ − CLIC5þ CXCL13þ HLAF þ TNFRSF17þ XCL2ð Þ
5
For patients with missing ΔΔCT values in any of the
ICS genes (n = 16), the score was not computed. The
prognostic performance of the ICS was assessed as de-
scribed above. As well, recursive partitioning analysis
was repeated using tumor grade, nodal status and ICS
values as input variables. In the context of this rpart
analysis, we explored whether grade could further strat-
ify the node-negative, ICS-low risk cases using Kaplan-
Meier curves and the log rank test. We also evaluated
whether the ICS remained prognostic among the node-
positive FFPE cases as a continuous variable and as a di-
chotomous variable using an optimal ICS threshold that
minimized the log rank test P-value and yielded subsets
with no less than 20% node-positive cases.
Cross-platform evaluation of the integrated cytokine
signature
We reaffirmed the prognostic value of the ICS as a
continuous variable (computed as described above and
Z-transformed) using two previously described pooled
expression microarray datasets of untreated node-negative
HRneg/Tneg cases as a continuous variable [22]. As well,
the rpart identified ICS threshold (0.2578) from thenode-negative HRneg FFPE cohort was then applied to
dichotomize these expression microarray datasets; and
DMFS associations were evaluated by Kaplan Meier sur-
vival analysis.
We also specifically assessed the association between
ICS and DMFS in the 95 microarray training set cases
defined as Tneg by bimodal filtering of ER/PR/HER2
gene expression in [4], using the ICS as a continuous
variable or dichotomized by the rpart determined thres-
hold value. To evaluate the ICS in the context of Tneg
molecular subtypes, we employed the 2,188 centroid
genes published in [4] that classify Tneg tumors into six
classes: immunomodulatory (IM), basal-like-1 (BL-1),
basal-like-2 (BL-2), mesenchymal (M), mesenchymal
stem-like (MSL) and luminal androgen receptor (LAR).
Centroid genes were mapped onto our dataset by gene
symbol; and genes represented by multiple probes were
collapsed by averaging. Consensus k-means clustering
(using all features and 80% sample subsampling) was
performed with the ConsensusClusterPlus package in R
[28]; and the six-cluster solution was selected. Hierarch-
ical clustering (ward linkage) of the centroid genes was
performed. Based on the pattern of expression of centroid
genes, each consensus cluster was assigned to one of the
six Tneg classes; and multivariate Cox proportional hazard
modeling was employed to evaluate whether ICS remained
prognostic after adjusting for Tneg molecular subtyping.
In other attempts to validate the ICS, we employed two
additional external Tneg/HRneg pooled microarray data-
sets (GSE31519 [24] and GSE25066 [29]) from the Gene
Expression Omnibus (GEO) database. For GSE31519, nor-
malized expression data were downloaded directly from
GEO; for GSE25066, raw expression data (.cel) files were
obtained, RMA normalized and adjusted for source bias
using ComBat [30] in R, and the HRneg subset (n = 185)
was then selected based on clinical (IHC) annotation. The
normalized expression datasets were annotated and col-
lapsed as previously described [22]; and in each cohort,
ICS values were computed and Z-transformed. Following
careful scrutiny of sample identities, all samples that were
included in the two previously described pooled node-
negative microarray cohorts were removed. Prognostic
value of the continuous ICS was evaluated using Cox
proportional hazard modeling.
Results
Prioritization of original 14 signature genes to derive a
new Buck-4 index
Parallel to our platform migration efforts, we further pri-
oritized the 14 genes within the original Buck-14 signature
using the microarray expression data from the pooled
training (n = 199) and validation (n = 75) cohorts previ-
ously reported [22]. Eleven genes (CXCL13, EXOC7,





















−4 −2 0 2 4
Value
Color Key
Figure 2 Hierarchical clustering of signature gene expression in the FFPE cohort measured by RT-PCR. ΔΔCT values are median-centered
within each individual sample source and clustered. Red/blue color intensity reflects magnitude of the ΔΔCT. Gray denotes missing value. Column
color bar denotes sample source (plum: Mayo Clinic, gold: Guy’s Hospital, green: California Pacific Medical Center). Row color bar reflects signature
membership (orange: IRS, turquoise: the four high priority Buck-14 genes, pale green: low priority Buck-14 genes not used in the
index computation).
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ation with DMFS by multivariate Cox modeling within
the training cohort. Of these, only five (CXCL13, CLIC5,
RGS4, RPS28//FLJ46061, ABO) also showed a trend as-
sociated with DMFS in the validation cohort by Cox
univariate or multivariate analysis. However, ABO did
not achieve a significant association with DMFS in any
of these analyses (Additional file 3: Table S3). These
prioritization efforts resulted in a minimal set of four
highest priority signature genes (CXCL13, CLIC5, RGS4
and RPS28//FLJ46061) which were used to compute the
Buck-4 index for prognostic comparison with the IR-7
index after RT-PCR measurement in the new cohort of
FFPE HRneg samples.
RT-PCR assay and prognostic evaluation of signature
genes in HRneg FFPE samples
Figure 2 shows a heatmap of the RT-PCR assayed expres-
sion levels of the Buck-14 and IR-7 signature genes in our
pooled FFPE cohort of 139 HRneg chemotherapy-naïve
breast cancer samples derived from three diverse geo-
graphic sources. Unsupervised clustering of the pooled
RT-PCR dataset did not reveal any apparent source biases
(Fisher test P = 0.66). Overall, expression levels of four
genes (MATN1, SSX3, HAPLN1 and XCL2) were too low
to be measured in more than 10% of the samples. Thenumber of samples with undetectable expression values
for each signature gene is listed by sample source in
Additional file 4: Table S4.
As individual outcome predictors, only three of the
RT-PCR measureable IR-7 and Buck-4 signature genes
(CLIC5, HLA-F and TNFRSF17) demonstrated signifi-
cant prognostic value within the pooled cohort of FFPE
HRneg cases (Additional file 5: Table S5). However,
when considered in combination as signatures, both the
IR-7 and Buck-4 indices were significantly associated
with DR. The prognostic performance of these indices
appeared similar, with hazard ratios (HR) of 1.47 (95%
CI: 1.07 to 2.02, P = 0.02) and 1.50 (95% CI: 1.08 to 2.07,
P = 0.02) associated with each unit increase in the Buck-
4 and IR-7 indices, respectively. As well, the predictive
power of these signatures, as assessed by the Harrell’s C
statistic, were comparable at 0.61 (95% CI: 0.52 to 0.70)
and 0.67 (95% CI: 0.57 to 0.76) for the Buck-4 and IR-7
indices, respectively.
Dichotomization of the pooled FFPE cohort by either the
Buck-4 (Figure 3A) or IR-7 (Figure 3B) at the median values
did not yield subsets with significant differences in DR
(log rank P = 0.0598 and 0.065, respectively). Recursive par-
titioning suggested that the best conditional risk prediction
model was one incorporating both clinical characteristics
(nodal status and tumor grade) and the IR-7 index
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Figure 3 Prognostic performance of the IR-7 and Buck-4 indices in the FFPE cohort. (A) Kaplan-Meier curves of pooled cohort dichotomized
at median Buck-4 index value, (B) Kaplan-Meier curves of pooled cohort dichotomized at median IR-7 index value, (C) rpart tree showing that nodal
status, IR-7 index and grade were selected in a conditional model which best predicts DR-free status. (D) Kaplan-Meier curves corresponding to
branches of the rpart tree. Color of the curves corresponds to terminal branch color: red = node-positive; skyblue = node-negative, high IR-7
index; blue = node-negative, low IR-7 index, grade III; dark blue = node negative, low IR-7 index, grade I/II.
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of 22 node-negative, low IR-7 and low (I/II) tumor grade
cases (Figure 3D) with excellent prognosis (94% DR free at
five years).
Combining IR-7 and Buck-4 signature genes into an opti-
mized 5-gene predictor
As the IR-7 and Buck-4 indices appeared to have similar
prognostic potential within this cohort of 139 FFPE HRneg
cases, we tested whether a better performing multigene
predictor could be determined by combining individual
genes from these different signatures. Figure 4A shows
that a specific combination of five genes (TNFRSF17,
CLIC5, HLA-F, CXCL13 and XCL2) yielded the best Cox
proportional hazard model fit for the pooled RT-PCR/
FFPE dataset. Ingenuity pathway analysis (IPA) linked
four of these five genes (TNFRSF17, CLIC5, HLA-F and
CXCL13) through two different cytokines, interleukin-
10 and interferon-γ (Figure 4B). XCL2, itself a chemo-
kine, did not appear connected to the other four geneswithin the IPA knowledge base. Given these functional
links, this optimized five-gene predictor is referred to as
an ICS, and it appears to have better prognostic value
than either the IR-7 or Buck-4 index, with higher HR as-
sociated with each unit increase in score: 1.82 (95% CI:
1.29 to 2.57), P = 0.0007. While its predictive power did
not appear significantly improved (Harrell’s C statistic:
0.68; 95% CI: 0.59 to 0.77), when its median value was
used to dichotomize the FFPE HRneg cases, the ICS
produced K-M curves with significant differences in DR
(Figure 4C, log rank P = 0.015).
Recursive partitioning once again demonstrated that
the optimal recurrence risk model included both clinical
(nodal status) and molecular (ICS) features (Figure 5A, B).
The minimum terminal branch size requirement pre-
cluded the selection of tumor grade to further partition
the node-negative low-ICS group. Stratification of this
group by grade (Figure 5C) yielded a subset of 19 cases
(27% of all node-negative low-ICS cases) with low (I/II)
tumor grade and an excellent prognosis (93% DR free at
AC
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Figure 4 Identification and prognostic performance of the five-gene Integrated Cytokine Score (ICS) in the FFPE cohort. (A) Plot of the
likelihood ratio P-values of the Cox proportional hazard model fit during forward stepwise selection. The smallest P-value, indicated by the arrow,
is achieved when five genes (TNFRSF17, CLIC5, HLA-F, CXCL13 and XCL2) are included in the signature. (B) The shortest path linking the five selected ICS
genes with connections as determined by Ingenuity Pathway Analysis software. (C) Kaplan-Meier curves of pooled cohort dichotomized at median ICS
value (red: ICS >Median, green: ICS≤Median).
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come of all node-negative low-ICS cases in this HRneg co-
hort, the subset of 51 high grade cases did not have
significantly worse outcome (88% DR free at five years, log
rank P = 0.282) (Figure 5C). Although our rpart modeling
constraints did not enable further stratification of the
node-positive cases, the ICS also proved significantly
prognostic for this higher stage group of HRneg tumors,
both as a continuous variable with a hazard ratio of 1.91
(95% CI: 1.19 to 3.05, P = 0.007) associated with one
unit increase of ICS, and as a dichotomous variable at
an optimal cut-point value (−0.4) (log rank P = 0.009)
(Figure 5D).
Cross platform and extended prognostic evaluation of the
five-gene ICS
Given that our optimized five-gene ICS represents a
composite from two different gene expression signature
sets measured by a new RT-PCR assay platform, we first
tried to reaffirm the prognostic value of the ICS in our
previously studied pooled microarray cohorts of node-negative and chemotherapy naïve HRneg/Tneg breast
cancer cases [22]. As a continuous variable, the ICS
proved to be significantly prognostic with hazard ratios
of 1.68 (95% CI: 1.29 to 2.18, P = 0.0001) and 1.82 (95%
CI: 1.16 to 2.87, P = 0.009) in each of the microarray
datasets. Although two of the ICS genes are derived and
subsequently prioritized from these datasets, thus bias-
ing us towards a positive finding, we note that the IR-7
signature from which three of the ICS genes (HLAF,
TNFRSF17, XCL2) were derived was not significantly
prognostic when similarly evaluated in the larger of
these microarray datasets (n = 199, P = 0.08). We then
employed the ICS threshold value identified by rpart
from the FFPE samples (Figure 5A) to dichotomize
these cohorts. As shown in Figure 6A, B, the rpart and
FFPE sample defined ICS cut-point produced signifi-
cant Kaplan-Meier curve separation in both dichoto-
mized datasets.
A well-defined Tneg subset (n = 95) from the larger of
the node-negative microarray cohorts was used to assess
the prognostic performance of the ICS in Tneg breast
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Figure 5 FFPE cohort outcome analyzed by recursive partitioning (rpart) using clinical parameters and the five-gene ICS. The rpart
analysis selected nodal status and Integrated Cytokine Score (ICS) in a conditional model which best predicts DR outcome. (A) rpart tree, (B)
Kaplan-Meier curves of rpart tree branches. Color of curves corresponds to terminal branch color: dark blue = LN-, ICS Low; skyblue = LN- ICS High;
red = LN+, (C) Kaplan-Meier curves of the LN-, ICS Low group (dark blue) further stratified by grade (I/II = dashed line, III = dotted line), (D) Kaplan-Meier
curves of the LN + rpart group (red) stratified by ICS at an optimal threshold, ICS = −0.4 (Low ICS = dashed line, High ICS = dotted line).
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Tneg molecular subtypes [4]. ICS was significantly prog-
nostic both as a continuous variable (hazard ratio: 1.48
(1.04 to 2.10), P = 0.027) and as a dichotomous variable
at the rpart determined ICS cut-point (Figure 6C).
When these Tneg cases were assigned into their six
Tneg molecular subtypes, all of the immunomodulatory
(IM) Tneg cases were found within the low-ICS group
(Figure 6D). However, the IM cases accounted for only
approximately 40% of the entire low-ICS group, with the
other 60% of good prognosis Tneg cases distributed
among the other Tneg transcriptional subtypes. In a
multivariate model that adjusts for the Tneg molecular
subtypes, ICS retained significant prognostic value either
as a continuous variable (hazard ratio associated with
each unit increase: 1.66 (1.03 to 2.68), P = 0.04) or as
dichotomized ICS-groups (hazard ratio of high relative
to low ICS group: 2.88 (1.20 to 6.91), P = 0.017). Con-
sistent with their initial description [4], these intrinsic
molecular subtypes did not possess significant prognosticvalue within this group of 95 node-negative Tneg cases
(P = 0.214).
To extend our prognostic evaluation of the five-gene
ICS beyond node-negative and chemotherapy naive breast
cancer cases, we turned to two other pooled cohorts of
heterogeneously staged and treated HRneg/Tneg breast
cancer cases: GSE31519 [24] and GSE25066 [29]. Careful
scrutiny of GSE31519 composition revealed cases that
were previously included in our earlier pooled cohorts.
When these overlapping cases were removed, ICS prognos-
tic significance was retained in the remaining GSE31519
cases (n = 271) which included 84 outcome annotated
Tneg cases that had received adjuvant chemotherapy
(hazard ratio associated with one unit increase: 1.25; 95%
CI: 1.06 to 1.48; P = 0.01). In the pooled GSE25066 dataset
containing 185 stage II to III Tneg cases that had all
received aggressive taxane-anthracycline neoadjuvant
therapy, the five-gene ICS also proved significantly prog-
nostic (HR = 1.3; 95% CI: 1.0 to 1.6; P = 0.04), whereas the
IR-7 signature did not (P = 0.08). Taken together, these
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Figure 6 Use of pooled microarray datasets to validate FFPE/RT-PCR derived and rpart determined ICS prognostic threshold. The rpart
identified ICS threshold for optimal risk stratification of FFPE LN- cases (0.2578) was applied to dichotomize outcome (DMFS) in two previously reported
microarray datasets representing 274 node-negative and adjuvant chemotherapy naïve HRneg/Tneg breast cancer cases [22]. Kaplan-Meier curves of
ICS dichotomized groups from (A) training and (B) validation HRneg microarray datasets (dark blue = LN-, ICS Low; skyblue = LN-, ICS High) and (C) the
Tneg subset (n = 95) of training cases. (D) Heatmap of Tneg subtype centroid genes within the six consensus clusters. Samples are arranged by
Tneg subtypes (dark blue: BL-1, darkgreen: M, orange: BL-2, skyblue: IM, red: LAR, and pale green: MSL) with their corresponding ICS group
assignment displayed below (dark blue: ICS Low, skyblue: ICS High). Color intensity of the heatmap reflects magnitude of gene expression on a
red-blue scale (red: positive, blue: negative).
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indicate that the prognostic value of ICS extends beyond
node-negative and chemotherapy naïve HRneg/Tneg cases,
to those of more advanced clinical stage and despite inter-
vention with aggressive adjuvant chemotherapy.
Discussion
HRneg and Tneg breast cancers are almost always
treated with systemic chemotherapy, despite reports in-
dicating that over two-thirds of early stage Tneg patients
conservatively managed without adjuvant chemotherapy
remain disease-free for five or more years [8,25]. Thus,
there is pressing clinical need for a robust clinical assay
that predicts HRneg and/or Tneg breast cancer recur-
rence risk to identify patients with inherently good prog-
nosis disease that may not require aggressive systemic
therapy for curative intent. This study represents the first
reported effort to translate two promising microarray-derived HRneg/Tneg predictive indices, the IR-7 [20] and
Buck-4 (a prioritized version of the Buck-14) [22] multi-
gene signatures, onto a multiplexed RT-PCR assay plat-
form for validation using RNA extracted from a newly
pooled FFPE collection of 139 chemotherapy-naïve HRneg
breast cancer specimens acquired from three diverse geo-
graphic sources. Our goal was to develop a signature
based on biologic differences that would (1) have clinical
significance and inform adjuvant or neoadjuvant therapy
decisions even if available tissue samples were limited, (2)
demonstrate sufficient robustness to cross assay platforms,
and (3) remain prognostic despite the inherent molecular
and clinical heterogeneity of HRneg and Tneg breast can-
cers. Figure 1 outlines the path we followed to refine and
then further validate the optimized five-gene ICS for this
purpose.
In contrast to the purely node-negative HRneg/Tneg
sample cohorts from which one of the two microarray-
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cohort of pooled FFPE samples we evaluated contained
29% (40/139) node-positive cases, potentially altering the
prognostic performance of both the Buck-4 and IR-7
predictors beyond the analytical influence of using a very
different gene expression assay platform. Nonetheless,
both of the two RT-PCR measured signatures retained
significant prognostic value within this new FFPE sample
set, as evident by their significant associations with out-
come (DR) when evaluated as continuous variables.
However, they could not dichotomize the FFPE cohort
into groups with significant outcome differences at a
median index threshold, suggesting potential for further
optimization.
The comparable prognostic performance of the Buck-4
and IR-7 indices in this FFPE cohort of HRneg breast
cancer samples was likely due to strong correlations be-
tween individual IR-7 and Buck-4 signature genes, as ob-
served in the unsupervised clustering analysis, where
genes from both signatures were similarly represented
within the two main gene clusters (Figure 2). Of note,
expression levels of two of the Buck-4 genes, CXCL13
and CLIC5, were significantly associated with all but one
(SPP1) of the IR-7 genes (data not shown), resulting in
highly correlated (Rp = 0.62, p = 8.0E-14) IR-7 and Buck-
4 indices. This degree of correlation between the two in-
dices was surprising given that only one of the Buck-4
genes, CXCL13, has any direct link to immune response
[22]. The other highly correlated Buck-4 gene, CLIC5, is
a calcium-regulated chloride channel protein linked to
cellular differentiation [31] but not to any reported
immune-related mechanisms, raising the possibility that
CLIC5 may be indirectly regulated through an immune
function modulator.
The relative expression patterns and prognostic value
of individual genes constituting the Buck-4 and IR-7 sig-
natures in these FFPE samples suggested that a better per-
forming predictor may be derived by combining specific
genes from both signatures. A best Cox proportional haz-
ard model fit identified the optimized five-gene combin-
ation referred to as the ICS, containing three of the IR-7
genes (TNFRSF17, HLA-F, XCL2) and two of the Buck-4
genes (CXCL13, CLIC5). This ICS also appeared as a bet-
ter predictor of distant recurrence risk than the IR-7 and
Buck-4 signatures when used as a dichotomous biomarker
at the median value cut-point (Figures 3 and 4C). The IPA
knowledge base linked together only four of the five ICS
genes, including CLIC5, via interconnections through
cytokines IL10 and IFN-γ, as illustrated in Figure 4B.
However, the apparently disconnected XCL2 gene (che-
mokine ligand 2), also referred to as lymphotactin-2, is a
well-documented immune system cytokine known to be
mechanistically involved in cancer cell migration and
proliferation [32,33]. Of additional note, two of the ICSgenes relate directly to B-cell function: TNFRSF17 is
expressed on mature B-cells and CXCL13 is a B-cell
attracting chemokine. Taken together, these common
immune system and cytokine links suggest that higher
levels of B-cell mediated signaling as reflected by lower
ICS values are associated with a lower risk of distant
metastatic recurrence by HRneg/Tneg breast cancers, a
conclusion also supported in part by a report that high
B-cell/low IL-8 gene expression is associated with good
prognosis Tneg breast cancers [24].
The five-gene ICS whether assayed in fresh/frozen pri-
mary HRneg/Tneg tumors by expression microarrays or
in FFPE samples by RT-PCR analysis, retains its prognos-
tic value regardless of primary tumor nodal involvement
or chemotherapy use. The prognostic value of the Buck-4
signature appears similarly robust (data not shown); in
contrast, the IR-7 index did not show significant outcome
associations in two of the four expression microarray data-
sets evaluated. Further comparisons between RT-PCR
measurements of these signatures in additional HRneg/
Tneg cohorts will be needed to ascertain whether ICS
remains the most robust and significant predictor of
metastatic outcome when assessed by a clinically rele-
vant assay.
Recursive partitioning of the chemotherapy-naïve FFPE
dataset based on nodal status, ICS and tumor grade
(I/II vs. III) was able to identify 27% of our node-negative
HRneg cases as having less than a 10% likelihood of ever
developing distant metastatic disease (Figure 5C), a clinic-
ally meaningful observation offering such patients a pre-
dictive rationale for opting out of aggressive adjuvant
chemotherapy. For perspective as a breast cancer prog-
nostic, this ICS identifiable very low risk subset of HRneg
breast cancer cases has a five-year distant recurrence risk
comparable to that of the low risk group identifiable by
the FDA-approved MammaPrint assay, as applied to unse-
lected (and largely HRpos) breast cancer cases [34]. We
note here that the only clinical parameters considered as
input to our recursive partitioning model were nodal
status and tumor grade; and that inclusion of additional
clinical variables (for example, tumor size, histologic type)
might further influence the algorithm’s selection of prog-
nostic parameters.
Multivariate Cox proportional hazard modeling con-
firmed that both nodal status and ICS (as a continuous
variable) were of independent prognostic value in our FFPE
dataset, with significant HR values of 3.8 (95% CI: 1.8 to
7.9; P = 0.0003) and 1.8 (95% CI: 1.3 to 2.6; P = 0.0007),
respectively. Interestingly, at an optimal cut-point, the
ICS was able to dichotomize the node-positive FFPE
cases into a very high risk group with only a 30% likeli-
hood of remaining free of distant metastatic recurrence
within five years, and a much lower risk group with com-
parable metastatic recurrence risk as the high ICS node-
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DR-free at five years) (Figure 5B, D). Since breast cancer
nodal involvement can be driven by both the clinical dur-
ation of a primary tumor as well as its intrinsic biology,
the observed prognostic independence of nodal status and
ICS suggests that the biological mechanisms driving
HRneg/Tneg nodal involvement are not tightly linked to
the immune/cytokine functions represented by ICS.
Despite the prognostic independence of ICS from nodal
status, we noted that the optimal ICS threshold for risk
stratification appeared different between the node-positive
and node-negative FFPE cases (−0.4 vs. 0.2578), even
though the distribution of ICS values between these sub-
sets appeared similar (data not shown). This highlights the
challenges in defining a single optimal cut-point for risk
stratification using heterogeneous populations of HRneg/
Tneg breast cancer cases, and provides further rationale
for the use of conditional risk models such as recursive
partitioning (rpart). Such challenges notwithstanding, we
were able to use the rpart determined ICS prognostic cut-
point from the RT-PCR measured node-negative FFPE
cases to dichotomize our previously employed pooled
microarray datasets of node-negative chemotherapy naive
HRneg/Tneg cases into low and high risk subgroups with
significant outcome differences (Figure 6A, B). As well,
this same prognostic cut-point significantly dichotomized
metastatic outcome in a well-defined subset of 95 Tneg
cases (Figure 6C), which we showed consisted of all six
previously defined intrinsic Tneg subtypes [4]. Interest-
ingly, despite the link between ICS and immune function,
approximately 60% of low-ICS Tneg cases were not
assigned to the IM subtype (Figure 6D). In keeping with
the observed prognostic independence of ICS on Tneg
molecular subtypes, there were no significant outcome
differences between the IM and non-IM Tneg cases
within the low ICS group (log rank P = 0.298), suggest-
ing that good prognosis Tneg cases with activated im-
mune responses (as reflected by low ICS) can be found
within all five subtypes, including basal-like (BL-1 and
BL-2) Tneg cases.
We did observe somewhat lower five-year distant
recurrence-free rates in the low ICS microarray subgroups
(82% in Figure 6A, 78% in Figure 6B, 75% in Figure 6C)
relative to the corresponding FFPE subgroup (88% in
Figure 5B) identified by the same ICS cut-off value. We at-
tribute these outcome differences associated with ICS di-
chotomization to multiple confounding factors including
heterogeneous HRneg/Tneg tumor populations, different
assay platforms, and scaling issues arising from the appli-
cation of a threshold ICS value derived using a mixed
node-negative and node-positive FFPE tumor population
to pure node-negative populations of fresh/frozen HRneg/
Tneg tumors. We expect to avoid many of these con-
founding issues with our planned validation study that willmeasure ICS by this newly described RT-PCR assay in sev-
eral hundred chemotherapy naïve and node-negative FFPE
HRneg/Tneg samples archived from a unique cohort of
patients who, between 1976 and 1985, entered the control
(untreated) arm of a large Swedish clinical trial.
Conclusions
Our studies demonstrate the successful migration of two
previously identified multigene HRneg/Tneg breast can-
cer prognostic signatures [20,22] onto a clinically applic-
able RT-PCR assay platform suitable for use with FFPE
tumor samples. While both these multigene signatures
proved to have some prognostic value in the new FFPE
sample set, combining the five best performing genes
from both signatures into an ICS produced an optimized
predictor of distant metastatic recurrence risk. Using the
ICS in a conditional risk model that also included nodal
status and tumor grade, we were able to identify a very
low-risk node-negative subset of HRneg/Tneg breast
cancers with less than 10% DR risk at five years, and a
high-risk node-positive subset with a nearly 70% chance
of developing a distant metastatic recurrence within five
years of initial diagnosis. Identifying patients diagnosed
with such good prognosis HRneg/Tneg tumors will
enable some to rationally decide not to undergo systemic
adjuvant chemotherapy, while those diagnosed with tu-
mors at highest risk of progressing to metastatic disease
may opt to enroll in adjuvant clinical trials evaluating
novel agents in combination with standard aggressive
chemotherapy. The prognostic value of this ICS appeared
robust and significant regardless of assay platform (micro-
array or RT-PCR), intrinsic Tneg subtype, primary tumor
nodal involvement, or adjuvant chemotherapy use. Fur-
ther validation in another outcome annotated archive of
FFPE breast cancers will be an important next step to-
wards the translation of this promising five-gene ICS into
the first clinically useful predictor of HRneg/Tneg breast
cancer metastatic risk.
Additional files
Additional file 1: Table S1. Sequences of primers used in the
multiplexed RT-PCR assays for signature gene assessment.
Additional file 2: Table S2. Table of raw CT and ΔΔCT values along
with the final normalized RT-PCR dataset employed in this study.
Additional file 3: Table S3. Results from the univariate and multivariate
Cox proportional hazard modeling of the previously reported [21] pooled
training (n = 199) and validation (n = 75) expression microarray datasets
used in the prioritization of the Buck-14 signature genes into the Buck-4 sig-
nature. Boxes with P-values <0.15 are highlighted in yellow. Names of high
priority genes are highlighted in red.
Additional file 4: Table S4. Table tallying the number of missing RT-
PCR ΔΔCT values within each gene signature by sample source.
Additional file 5: Table S5. Prognostic significance of individual RT-
PCR measured signature genes in FFPE cohort assessed by univariate
Cox regression analysis.
Yau et al. Breast Cancer Research 2013, 15:R103 Page 13 of 14
http://breast-cancer-research.com/content/15/5/R103Abbreviations
BL-1: Basal-like-1; BL-2: Basal-like-2; Buck-14: Multigene predictor of hormone
receptor/triple negative breast cancer risk with 14 genes; Buck-4
signature: Buck-14 signature condensed to only four high priority genes;
CPMC: California Pacific Medical Center; CSR/wound-response: Core serum
response signature; DMFS: Distant metastasis free survival; DR: Distant
recurrence; EMC-76: 76-gene Veridex signature; ER: Estrogen receptor;
FFPE: Formalin fixed paraffin embedded; HER2: Human epidermal growth
factor receptor 2; HRneg: Hormone receptor negative; HRpos: Hormone
receptor positive; ICS: Integrated cytokine signature; IFN: Interferon;
IL-10: Interleukin-10; IM: Immunomodulatory; IR-7: Immune response
signature with seven genes; LAR: Luminal androgen receptor; LN: Nodal status;
LN-: Node negative; LN+: Node positive; M: Mesenchymal; MS-14: Celera
14-gene metastasis score; MSL: Mesenchymal stem-like; N0,1: N Stage 0 or 1;
p53: p53-mutation status predictor; PR: Progesterone receptor; Rp: Pearson
correlation coefficient; RT-PCR: Reverse transcriptase polymerase chain reaction;
STAT1: Statin 1; T1,2: T Stage I or II; TN-45: Triple negative prognostic signature
with 45 genes; Tneg: Triple negative.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CY identified all of the public datasets, carried out all of the biostatistical and
informatic analyses, helped formulate the study conclusions and drafted the
manuscript. JS led the Celera team including SK and AW, who together
extracted the FFPE samples for RNA, designed, ran and analyzed the
multi-plexed RT-PCR reactions. AD and JNI provided the Mayo Clinic samples.
CG and AT provided the Guy’s Hospital samples. FW provided the CPMC
samples and DM provided statistical consultation. LE and CB co-initiated
and co-coordinated the project, guided the study design, supervised all
data curation and analysis, finalized all study conclusions and manuscript
writing. All coauthors reviewed and approved the final manuscript.
Acknowledgements
The authors wish to thank Cindy Christopherson and Monica Chang for the
challenging development of the multiplex PCR TaqMan assays for the
various scores as well as careful and accurate multiplex RT-PCR profiling for
the study. This project was supported in part by NIH grants P50-CA58207
(UCSF Breast SPORE), P50-CA116201 (Mayo Clinic Breast Cancer SPORE),
U24-CA14358 (TCGA-GDAC); a California Breast Cancer Research Program
Translational Research Award (18OB-0057); and Hazel P. Munroe memorial
funding (Buck Institute). This research was also supported in part by Cancer
Research UK and the Experimental Cancer Medicine Centre at KCL with
patient tissue samples provided by Guy’s and St Thomas’ Breast Tissue and
Data Bank, which is supported by the Department of Health via the National
Institute for Health Research (NIHR) comprehensive Biomedical Research
Centre award.
Author details
1Buck Institute for Research on Aging, Novato, CA, USA. 2Helen Diller Family
Comprehensive Cancer Center, University of California, San Francisco, CA,
USA. 3Celera/Quest Diagnostics, 1401 Harbor Bay Parkway, Alameda, CA
94502, USA. 4Mayo Clinic Cancer Center, Mayo Clinic, 200 First St. S.W.,
Rochester, MN 55905, USA. 5Breakthrough Breast Cancer Research Unit, Guy’s
Hospital, King’s Health Partners AHSC, King’s College London School of
Medicine, London, UK. 6Breast Tissue and Data Bank, Guy’s Hospital, King’s
Health Partners AHSC, King’s College London School of Medicine, London, UK.
Received: 5 April 2013 Accepted: 21 October 2013
Published: 31 October 2013
References
1. Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J
Med 2010, 363:1938–1948.
2. Hudis CA, Gianni L: Triple-negative breast cancer: an unmet medical
need. Oncologist 2011, 16:1–11.
3. Irshad S, Ellis P, Tutt A: Molecular heterogeneity of triple-negative breast
cancer and its clinical implications. Curr Opin Oncol 2011, 23:566–577.
4. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y,
Pietenpol JA: Identification of human triple-negative breast cancer subtypesand preclinical models for selection of targeted therapies. J Clin Invest 2011,
121:2750–2767.
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA,
Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical
features and patterns of recurrence. Clin Cancer Res 2007, 13:4429–4434.
6. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R,
Clemons M: Survival outcomes for patients with metastatic triple-negative
breast cancer: implications for clinical practice and trial design. Clin Breast
Cancer 2009, 9:29–33.
7. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H:
Breast cancer subtypes and the risk of local and regional relapse. J Clin
Oncol 2010, 28:1684–1691.
8. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait
W, Toppmeyer D: Locoregional relapse and distant metastasis in
conservatively managed triple negative early-stage breast cancer. J Clin
Oncol 2006, 24:5652–5657.
9. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL,
van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM,
Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling
predicts clinical outcome of breast cancer. Nature 2002, 415:530–536.
10. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K,
Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger
H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B,
Waldman F: Risk estimation of distant metastasis in node-negative, estrogen
receptor-positive breast cancer patients using an RT-PCR based prognostic
expression signature. BMC Cancer 2008, 8:339.
11. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D,
Foekens JA: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet 2005, 365:671–679.
12. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He
YD, van’t Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ:
Robustness, scalability, and integration of a wound-response gene ex-
pression signature in predicting breast cancer survival. Proc Natl Acad Sci
USA 2005, 102:3738–3743.
13. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG,
Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N:
A multigene assay to predict recurrence of tamoxifen-treated, node-
negative breast cancer. N Engl J Med 2004, 351:2817–2826.
14. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P,
Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human
breast cancer predicts mutation status, transcriptional effects, and
patient survival. Proc Natl Acad Sci USA 2005, 102:13550–13555.
15. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P,
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten
D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene expres-
sion profiling in breast cancer: understanding the molecular basis of
histologic grade to improve prognosis. J Natl Cancer Inst 2006,
98:262–272.
16. Pusztai L: Gene expression profiling of breast cancer. Breast Cancer Res
2009, 11:S11.
17. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B,
Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M,
Delorenzi M: Meta-analysis of gene expression profiles in breast cancer:
toward a unified understanding of breast cancer subtyping and prognosis
signatures. Breast Cancer Res 2008, 10:R65.
18. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G,
Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with
breast cancer clinical outcome depend on the molecular subtypes. Clin
Cancer Res 2008, 14:5158–5165.
19. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA,
Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y,
Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L,
Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade
OI, Bernard PS, et al: The molecular portraits of breast tumors are
conserved across microarray platforms. BMC Genomics 2006, 7:96.
20. Teschendorff AE, Caldas C: A robust classifier of high predictive value to
identify good prognosis patients in ER-negative breast cancer. Breast
Cancer Res 2008, 10:R73.
21. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C: An immune
response gene expression module identifies a good prognosis
Yau et al. Breast Cancer Research 2013, 15:R103 Page 14 of 14
http://breast-cancer-research.com/content/15/5/R103subtype in estrogen receptor negative breast cancer. Genome Biol
2007, 8:R157.
22. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC: A multigene
predictor of metastatic outcome in early stage hormone receptor-negative
and triple-negative breast cancer. Breast Cancer Res 2010, 12:R85.
23. Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY:
Molecular characteristics and metastasis predictor genes of triple-negative
breast cancer: a clinical study of triple-negative breast carcinomas. PLoS
One 2012, 7:e45831.
24. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R,
Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M:
A clinically relevant gene signature in triple negative and basal-like
breast cancer. Breast Cancer Res 2011, 13:R97.
25. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE,
Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC:
Biologic markers determine both the risk and the timing of recurrence
in breast cancer. Breast Cancer Res Treat 2011, 129:607–616.
26. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, Lumley T,
Maechler M, Magnusson A, Moeller S, Schwartz M, Venables B: gplots: various
R programming tools for plotting data. In R package version 2.11.0 edition;
2012.
27. Therneau T, Atkinson B, Ripley B: rpart: recursive Partitioning. In R package
version 4.1-1 edition. ; 2013.
28. Wilkerson MD, Hayes DN: ConsensusClusterPlus: a class discovery tool
with confidence assessments and item tracking. Bioinformatics 2010,
26:1572–1573.
29. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T,
Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R,
Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N,
Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A,
O’Shaughnessy J, Hortobagyi GN, Symmans WF: A genomic predictor of
response and survival following taxane-anthracycline chemotherapy
for invasive breast cancer. JAMA 2011, 305:1873–1881.
30. Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 2007,
8:118–127.
31. D’Angelo MA, Gomez-Cavazos JS, Mei A, Lackner DH, Hetzer MW: A change
in nuclear pore complex composition regulates cell differentiation.
Dev Cell 2012, 22:446–458.
32. Kim M, Rooper L, Xie J, Rayahin J, Burdette JE, Kajdacsy-Balla AA, Barbolina MV:
The lymphotactin receptor is expressed in epithelial ovarian carcinoma and
contributes to cell migration and proliferation. Mol Cancer Res 2012,
10:1419–1429.
33. Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D,
Myers RM, Kuster N, Costa FP, Barbault A, Pasche B: Cancer cell proliferation is
inhibited by specific modulation frequencies. Br J Cancer 2012, 106:307–313.
34. Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, d’Assignies MS,
Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A,
Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ, TRANSBIG
Consortium: Validation and clinical utility of a 70-gene prognostic signature
for women with node-negative breast cancer. J Natl Cancer Inst 2006,
98:1183–1192.
doi:10.1186/bcr3567
Cite this article as: Yau et al.: An optimized five-gene multi-platform pre-
dictor of hormone receptor negative and triple negative breast cancer
metastatic risk. Breast Cancer Research 2013 15:R103.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
